PSTV
HealthcarePlus Therapeutics, Inc.
$0.56
+$0.00 (+0.00%)
Jan 5, 2026
Price History (1Y)
Analysis
Plus Therapeutics, Inc. is a biotechnology company operating in the healthcare sector. The company's market capitalization is $77.08 million, and its revenue for the trailing twelve months (TTM) stands at $5.26 million. Plus Therapeutics employs 21 individuals. The company's financial health is marked by significant losses, with a net income of -$20,576,000 for the TTM period. Its gross margin, operating margin, and profit margin are negative (-45.0%, -320.8%, and 0.0%, respectively). The return on assets (ROA) is -65.6%, indicating substantial losses relative to total assets. Plus Therapeutics has a debt-to-equity ratio of 127.05, and its current ratio is 1.29. The company's valuation context is characterized by negative earnings growth (-4.1% year-over-year) and significant losses in recent periods. The forward price-to-earnings (P/E) ratio is -4.01, and the price to book ratio is 14.76.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Plus Therapeutics, Inc.
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company's lead radiotherapeutic candidate is REYOBIQ, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers by intra-arterial injection. In addition, it develops and commercializes laboratory-developed tests, such as the CNSide Test to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Houston, Texas.
Visit website →Key Statistics
- Market Cap
- $77.08M
- P/E Ratio
- N/A
- 52-Week High
- $2.31
- 52-Week Low
- $0.16
- Avg Volume
- 6.77M
- Beta
- 0.84
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 21